The University of Pennsylvania's clinical trial aims to innovate the implementation of genomic medicine by utilizing behavioral economics and advanced EHR systems. This approach targets a growing market for genetic testing, particularly as indications expand and the clinical utility of genetic results becomes increasingly recognized. The trial's focus on non-geneticist clinician and patient nudges positions it uniquely within the competitive landscape, potentially leading to improved patient outcomes and increased adoption of genetic testing across diverse health systems. The findings could influence reimbursement strategies and policy-making in genomic medicine, presenting opportunities for partnerships with EHR vendors and genetic testing laboratories.